Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-02T20:53:43.042Z Has data issue: false hasContentIssue false
  • English
  • Français

Diminished Susceptibility to Daptomycin Accompanied by Clinical Failure in a Patient With Methicillin-Resistant Staphylococcus aureus Bacteremia

Published online by Cambridge University Press:  21 June 2016

David Hirschwerk ,
Christine C. Ginocchio ,
Maureen Bythrow  and
Susan Condon
David Hirschwerk*
Affiliation:
Department of Medicine, New York University School of Medicine, and Division of Infectious Diseases, North Shore University Hospital, Manhasset, New York
Christine C. Ginocchio
Affiliation:
Microbiology, Virology, and Molecular Diagnostics, Department of Laboratory Medicine, Lake Success, New York
Maureen Bythrow
Affiliation:
Department of Microbiology, North Shore-Long Island Jewish Health System Laboratories, Lake Success, New York
Susan Condon
Affiliation:
Department of Microbiology, North Shore-Long Island Jewish Health System Laboratories, Lake Success, New York
*
Division of Infectious Diseases, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

We cared for a patient with methicillin-resistant Staphylococcus aureus bacteremia who experienced clinical failure with daptomycin. The failure was accompanied by progressive elevation of the daptomycin minimum inhibitory concentration during treatment. DNA fingerprinting confirmed that the minimum inhibitory concentration elevation occurred within the same strain of methicillin-resistant Staphylococcus aureus. This observation provides important new information to clinicians who adopt this promising drug for treatment of serious infections caused by methicillin-resistant Staphylococcus aureus.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 27 , Issue 3 , March 2006 , pp. 315 - 317
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Chang, S, Sievert, DM, Hageman, JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342–1347.CrossRefGoogle ScholarPubMed
2.Howden, BP, Ward, PB, Charles, PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521–528.Google Scholar
3.Carpenter, CF, Chambers, HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994–1000.CrossRefGoogle ScholarPubMed
4.Akins, RL, Rybak, MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45:454–459.CrossRefGoogle Scholar
5.Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2003.Google Scholar
6.LaPlante, KL, Rybak, MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4465–4472.CrossRefGoogle Scholar
7.Cha, R, Rybak, MJ. Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003; 47:539–546.Google Scholar
8.Steenbergen, JN, Alder, J, Thome, GM, Tally, FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005; 55:283–288.Google Scholar
9.Sakoulas, G, Eliopoulos, GM, Adler, J, Thauvin-Eliopoulos, C. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714–1718.Google Scholar
10.Rand, KH, Houck, HJ. Synergy of daptomycin with oxacillin and other B-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:2871–2875.Google Scholar
11.Mohan, SS, Mcdermott, BP, Cunha, BA. Methicillin-resistant Staphylococcus aureus prosthetic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 2005; 34:69–71.Google Scholar
12.Silverman, JA, Oliver, N, Andrew, T, Li, T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799–1802.Google Scholar
13.Mangilli, A, Bica, I, Snydman, DR, Hamer, DH. Daptomycin-resistant, methicillin-resistant, Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058–1060.Google Scholar
14.Wise, R, Andrews, JM, Ashby, JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48:563–567.Google Scholar